Although inflammation/fibrosis and hepatic steatosis are believed to increase PAI-1 levels4, 5, 6, 7, our immunohistochemical (IHC) studies showed that the influence of hepatic fibrosis and steatosis on hepatic PAI-1 expression of CHC patients was negligible. This evidence concerns the gene SERPINE1 and fatty liver disease.